CONTEXT: Adiponectin is atheroprotective in the laboratory, but prospective studies have shown opposite associations with cardiovascular disease (CVD) in healthy middle-aged populations (protective) and older cohorts (adverse). Whether this relates to different proportions of high-molecular-weight (HMW) adiponectin is unknown. OBJECTIVE: The aim of the study was to test the hypothesis that total adiponectin is directly associated, but HMW adiponectin is inversely related, with CVD in older adults. DESIGN, SETTING, AND PARTICIPANTS: We evaluated 3290 participants free of prevalent CVD in a longitudinal cohort study of U.S. adults aged 65 yr and older. MAIN OUTCOME MEASURES: We measured incident CVD (n = 1291), comprising coronary heart disease and ischemic stroke. RESULTS: Total and HMW adiponectin were tightly correlated (r = 0.94). Cubic splines adjusted for potential confounders revealed that the associations of total and HMW adiponectin with CVD were U-shaped, with inflection points of 20 and 10 mg/liter, respectively. After controlling for potential confounding, levels of total and HMW adiponectin below these cutpoints tended to be inversely associated with incident CVD, driven by their significant or near-significant relations with coronary heart disease [hazard ratio (HR), 0.85 per sd increase; 95% confidence interval (CI), 0.75-96; and HR, 0.87; 95% CI, 0.75-1.01, respectively]. These associations were abrogated by additional inclusion of putative metabolic intermediates. Above these cutpoints, however, both total and HMW adiponectin were significantly directly associated with CVD after adjustment for confounders and, particularly, mediators (HR, 1.20 per sd increase; 95% CI, 1.06-1.35; and HR, 1.12; 95% CI, 1.02-1.24, respectively). CONCLUSION: In community-living elders, total and HMW adiponectin showed similar U-shaped relationships with CVD. The inverse relation in the lower range, but not the direct association at the higher end, disappeared after inclusion of putative intermediates, suggesting that high levels may reflect adverse processes separate from adiponectin's beneficial glycometabolic properties.
CONTEXT: Adiponectin is atheroprotective in the laboratory, but prospective studies have shown opposite associations with cardiovascular disease (CVD) in healthy middle-aged populations (protective) and older cohorts (adverse). Whether this relates to different proportions of high-molecular-weight (HMW) adiponectin is unknown. OBJECTIVE: The aim of the study was to test the hypothesis that total adiponectin is directly associated, but HMW adiponectin is inversely related, with CVD in older adults. DESIGN, SETTING, AND PARTICIPANTS: We evaluated 3290 participants free of prevalent CVD in a longitudinal cohort study of U.S. adults aged 65 yr and older. MAIN OUTCOME MEASURES: We measured incident CVD (n = 1291), comprising coronary heart disease and ischemic stroke. RESULTS: Total and HMW adiponectin were tightly correlated (r = 0.94). Cubic splines adjusted for potential confounders revealed that the associations of total and HMW adiponectin with CVD were U-shaped, with inflection points of 20 and 10 mg/liter, respectively. After controlling for potential confounding, levels of total and HMW adiponectin below these cutpoints tended to be inversely associated with incident CVD, driven by their significant or near-significant relations with coronary heart disease [hazard ratio (HR), 0.85 per sd increase; 95% confidence interval (CI), 0.75-96; and HR, 0.87; 95% CI, 0.75-1.01, respectively]. These associations were abrogated by additional inclusion of putative metabolic intermediates. Above these cutpoints, however, both total and HMW adiponectin were significantly directly associated with CVD after adjustment for confounders and, particularly, mediators (HR, 1.20 per sd increase; 95% CI, 1.06-1.35; and HR, 1.12; 95% CI, 1.02-1.24, respectively). CONCLUSION: In community-living elders, total and HMW adiponectin showed similar U-shaped relationships with CVD. The inverse relation in the lower range, but not the direct association at the higher end, disappeared after inclusion of putative intermediates, suggesting that high levels may reflect adverse processes separate from adiponectin's beneficial glycometabolic properties.
Authors: Alexandra D Ogorodnikova; Sylvia Wassertheil-Smoller; Peter Mancuso; MaryFran R Sowers; Swapnil N Rajpathak; Matthew A Allison; Alison E Baird; Beatriz Rodriguez; Rachel P Wildman Journal: Stroke Date: 2010-05-27 Impact factor: 7.914
Authors: Jorge R Kizer; Mary L Biggs; Joachim H Ix; Kenneth J Mukamal; Susan J Zieman; Ian H de Boer; Dariush Mozaffarian; Joshua I Barzilay; Elsa S Strotmeyer; Jose A Luchsinger; Mitchell S V Elkind; W T Longstreth; Lewis H Kuller; David S Siscovick Journal: Am J Epidemiol Date: 2010-12-01 Impact factor: 4.897
Authors: Jorge R Kizer; Alice M Arnold; Elsa S Strotmeyer; Diane G Ives; Mary Cushman; Jingzhong Ding; Stephen B Kritchevsky; Paulo H M Chaves; Calvin H Hirsch; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2010-07-08 Impact factor: 6.053
Authors: J Poehls; C L Wassel; T B Harris; P J Havel; M M Swarbrick; S R Cummings; A B Newman; S Satterfield; A M Kanaya Journal: Diabetologia Date: 2009-01-22 Impact factor: 10.122
Authors: An M Van Berendoncks; Anne Garnier; Paul Beckers; Vicky Y Hoymans; Nadine Possemiers; Dominique Fortin; Wim Martinet; Viviane Van Hoof; Christiaan J Vrints; Renée Ventura-Clapier; Viviane M Conraads Journal: Circ Heart Fail Date: 2010-01-26 Impact factor: 8.790
Authors: Christopher R deFilippi; Robert H Christenson; John S Gottdiener; Willem J Kop; Stephen L Seliger Journal: J Am Coll Cardiol Date: 2010-02-02 Impact factor: 27.203
Authors: Fima Macheret; Traci M Bartz; Luc Djousse; Joachim H Ix; Kenneth J Mukamal; Susan J Zieman; David S Siscovick; Russell P Tracy; Susan R Heckbert; Bruce M Psaty; Jorge R Kizer Journal: Heart Date: 2015-04-08 Impact factor: 5.994
Authors: Michal Kasher Meron; Shuo Xu; Marshall J Glesby; Qibin Qi; David B Hanna; Kathryn Anastos; Robert C Kaplan; Jorge R Kizer Journal: AIDS Res Hum Retroviruses Date: 2019-09-03 Impact factor: 2.205
Authors: Rachel H Mackey; Kathleen M McTigue; Yuefang F Chang; Emma Barinas-Mitchell; Rhobert W Evans; Lesley F Tinker; Cora E Lewis; JoAnn E Manson; Marcia L Stefanick; Barbara V Howard; Lawrence S Phillips; Simin Liu; Doina Kulick; Lewis H Kuller Journal: BBA Clin Date: 2015-06